Generic phentermine/topiramate ER launches in the US

Teva Pharmaceuticals started US distribution of generic Qsymia — phentermine hydrochloride and topiramate extended-release capsules — on May 7, 2025, listing all four approved strengths: 3.75 mg/23 mg, 7.5 mg/46 mg, 11.25 mg/69 mg and 15 mg/92 mg ^[1]. A second manufacturer, Dr. Reddy's Laboratories, received FDA approval and a marketing start date of June 12, 2025 for the same four strengths ^[1].

The approvals build on an earlier clearance for Actavis Labs FL (a Teva company) dated June 25, 2024 ^[1]. The brand, made by VIVUS, was first approved on July 17, 2012 ^[1]. All of the generic listings are rated AB, the FDA's code for products considered therapeutically equivalent to the brand ^[1].

What the prices look like

The biggest change shows up at the discount-coupon counter. GoodRx lists typical coupon prices for 30 generic capsules at $59.72 for 3.75 mg/23 mg, $59.05 for 7.5 mg/46 mg, and $62.80 for both 11.25 mg/69 mg and 15 mg/92 mg ^[2]. Coupon prices for brand-name Qsymia at the same doses run $170.92 to $188.64 ^[2].

Average cash prices without any discount are much higher. GoodRx puts brand Qsymia at $249.32 (3.75/23), $258.08 (7.5/46), $273.42 (11.25/69) and $275.66 (15/92) for 30 capsules, with average generic cash prices of $228.08, $165.94, $251.35 and $251.10 respectively ^[2].

Sources do not fully agree on the generic's going rate. Drugs.com's price guide shows generic phentermine/topiramate ER starting at $169.28 for 30 capsules of 3.75 mg/23 mg, $174.58 for 7.5 mg/46 mg and $186.68 for 11.25 mg/69 mg ^[1] — well above the coupon figures GoodRx reports ^[2]. Pharmacy, location, dose and whether a discount card is used all affect what a person actually pays ^[2]. GoodRx also notes that Qsymia is a controlled substance and some states do not allow coupons to be used for these medications ^[2].

Insurance is still a hurdle

Coverage data cited by GoodRx, from Managed Markets Insight & Technology as of May 12, 2025, shows 89.6% of enrollees in commercial plans outside the ACA marketplace have coverage for Qsymia 7.5 mg/46 mg, but 70.5% face prior authorization ^[2]. Coverage falls to 38.3% in Medicaid plans, 33.2% in ACA marketplace plans and just 1.9% in Medicare Advantage and Part D plans ^[2]. Plans may prefer the generic over the brand ^[2].

VIVUS runs two brand savings programs: a savings card that covers up to $65 of a commercial copay after the patient pays the first $70, or $75 off per month for people without insurance coverage, and Qsymia Engage, a home-delivery program advertised at as little as $70 for a 90-day supply ^[2]. People with Medicare or Medicaid are not eligible for the savings card ^[2].

Why it matters for patients

Phentermine/topiramate ER is an oral, non-injectable weight-management option that has been on the market since 2012 and is now available as a low-cost generic ^[1][2]. For people who cannot get a GLP-1 medication covered — a common situation in Medicare, where obesity drugs are largely excluded — a roughly $60-a-month cash option changes the arithmetic of what is affordable ^[2].

The trade-off is effectiveness. In Qsymia studies cited by GoodRx, average weight loss was about 8% to 10% after 56 weeks, and about 70% of participants lost at least 5% of their starting body weight on the highest dose over a year ^[2]. That is a different scale of result than what has been reported for semaglutide or tirzepatide, though the sources here do not make a head-to-head comparison.

Two suppliers instead of one also matters for supply stability, though whether more manufacturers will enter is not yet known.

What happens next

Dr. Reddy's product carries a June 12, 2025 marketing start date, so a third-party alternative to Teva's version entered the market roughly five weeks after Teva's launch ^[1]. VIVUS patents listed in the FDA's Orange Book run to June 9, 2028, June 14, 2029 and May 15, 2029 ^[1]; the sources do not explain how generics reached the market ahead of those dates, and details of any litigation or settlement are not disclosed in the material reviewed here. Prices for generics typically move as more sellers compete, but the sources do not project future pricing.